Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 208 Next >>

Filter Applied: review article (Click to remove)

Practice Guideline Summary: Treatment of Restless Leg Syndrome in Adults
Neurol 87:2585-2593, Winkelman, J.W.,et al, 2016

Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013

Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010

Tourettes Syndrome
NEJM 363:2332-2338, Kurlan,R., 2010

Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009

Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008

Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008

Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007

Restless Legs Syndrome: Is Treatable But Under-Recognised
BMJ 333:457-458, Medcalf,P. &Bhatia,K.P., 2006

Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006

Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005

Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003

Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003

Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
NEJM 349:2023-2033, Colao,A.,et al, 2003

Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000

Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999

Management of Pituitary Tumors
Ann Int Med 129:472-483, Shimon,I.&Melmed,S., 1998

Restless Legs Syndrome:Clinicoetiologic Correlates
Neurol 47:1435-1441, Ondo,W.&Jankovic,J., 1996

Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995

Diagnosis and Management of Pituitary Tumours
BMJ 308:1087-1091, Levy,A.&Lightman,S.L., 1994

Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994

Drug Therapy of Migraine
NEJM 329:1476-1483, Welch,K.M.A., 1993

Acromegaly:Treatment After 100 Years
BMJ 307:1505-1506, Wass,J.A.H., 1993

Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991

Acromegaly
NEJM 322:966-977, Melmed,S., 1990

Neuroleptic Malignant Syndrome, Review of Response to Therapy
Arch Int Med 149:1927-1931, Rosenberg,M.R.&Green,M., 1989

International Symposium on Early Dopamine Agonist Therapy of Parkinson's Disease
Arch Neurol 45:204-208, Kurlan,R., 1988

Hyperprolactinaemia, Common and Treatable
BMJ 297:701-702, Hartog,M.&Hull,M.G.R., 1988

Prolactinomas
Editorial, BMJ 290:182-1841985., Grossman,A.,et al, 1985

Neuroleptic Malignant Syndrome
NEJM 313:163-166, Guze,B.H.,et al, 1985

Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022

Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021

Migraine
NEJM 383:1866-1876, Ashina, M., 2020

Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014

Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults
Neurol 78:1337-1345, Silberstein,S.D.,et al, 2012

Acute and Preventive Pharmacologic Treatment of Cluster Headache
Neurol 75:463-473, Francis,G.J., et al, 2010

Triptan Therapy in Migraine
NEJM 363:63-70, Loder,E., 2010

Headache and Pregnancy
The Neurologist 14:108-119, Menon,R. &Bushnell,C.D., 2008

Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008

Practice Parameter: Pharmacological Treatment of Migraine Headache in Children and Adolescents
Neurol 63:2215-2224, Lewis,D.,et al, 2004

Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002

The Safety of Triptans in the Treatment of Patients with Migraine
Am J Med 112:135-140, Jamieson,D.G., 2002

What Matters is Not the Differences Between Triptans, but the Differences Between Patients
Arch Neurol 58:1481-1482, Saper,J.R., 2001

Triptans Are All Different
Arch Neurol 58:1479-1480,1482, Rapoport,A.M.&Tepper,S.J., 2001

Tourette's Syndrome
NEJM 345:1184-1192, Jankovic,J., 2001

Oral Triptans (serotonin 5-HT 1B/1D agnosists) in Acute Migraine Treatment: A Meta-analysis of 53 Trials
Lancet 358:1668-1675, Ferrari,M.D.,et al, 2001

Triptans and Migraine
Lancet 355:860-861, Bateman,D.N., 2000

Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000

Optimizing the Dose of Zolmitriptan (Zomig, *311C90) for the Acute Treatment of Migraine
Neurol 49:1210-1218, 11931997., Rapoport,A.M.,et al, 1997



Showing articles 0 to 50 of 208 Next >>